Second Sight Medical Products, Inc. (EYES) Stock Analysis

Why this analysis is different

• A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Second Sight Medical Products, Inc. (EYES) Healthcare & Pipeline Overview

Second Sight Medical Products, acquired by Nano Precision Medical, focuses on developing and marketing implantable visual prosthetics for blind individuals. Their primary product is the Orion Visual Cortical Prosthesis System, targeting vision loss due to conditions like glaucoma and diabetic retinopathy. The company operates within the medical devices industry.

What Is the Investment Thesis for EYES?

Second Sight Medical Products, Inc. presents a high-risk, high-reward investment profile, primarily due to its focus on innovative but unproven technology in the visual prosthetics field. The company's success hinges on the clinical efficacy and market acceptance of the Orion Visual Cortical Prosthesis System. With a market capitalization of $3.61M and a negative P/E ratio of -0.32, the company's valuation is speculative, reflecting the potential of its technology rather than current profitability. A gross margin of 50.0% indicates potential for profitability if sales volume increases. The company's high beta of 2.56 suggests significant volatility relative to the broader market. Key growth catalysts include successful clinical trials, regulatory approvals, and commercialization of the Orion system. The reverse merger with Nano Precision Medical, Inc. introduces additional uncertainty and potential synergies.

Based on FMP financials and quantitative analysis

EYES Key Highlights

Market Cap: $0.21B indicates the company's size and market value.

• P/E Ratio: -0.32 reflects the company's current lack of profitability.
• Profit Margin: 15559645.8% suggests potential for high profitability if the company can scale its operations effectively.
• Gross Margin: 50.0% demonstrates the company's ability to generate revenue after accounting for the cost of goods sold.
• Beta: 2.56 indicates high volatility compared to the market.

Who Are EYES's Competitors?

EYES is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are EYES's Key Strengths?

Proprietary Orion Visual Cortical Prosthesis System.

• Focus on addressing unmet needs in blindness.
• Experienced management team.
• Potential for high profit margins.

What Are EYES's Weaknesses?

Limited commercial success to date.

• High research and development costs.
• Dependence on regulatory approvals.
• Small number of employees.

What Could Drive EYES Stock Higher?

Regulatory approvals for the Orion Visual Cortical Prosthesis System in key markets.

• Clinical trial results demonstrating the safety and efficacy of the Orion system.
• Strategic partnerships with research institutions and hospitals.
• Technological advancements in visual prosthetics.

What Are the Key Risks for EYES?

Competition from alternative therapies for blindness.

• Regulatory delays and uncertainties.
• Product liability claims.
• Limited commercial success and financial resources.
• Dependence on key personnel.

What Are the Growth Opportunities for EYES?

• Orion Visual Cortical Prosthesis System Commercialization: The successful commercialization of the Orion system represents a significant growth opportunity for Second Sight. This includes securing regulatory approvals, establishing manufacturing capabilities, and developing a robust sales and marketing strategy. The addressable market includes individuals blinded by glaucoma, diabetic retinopathy, optic nerve damage, and eye injury. This market is estimated to grow as the population ages and the prevalence of these conditions increases. Timeline: Ongoing, dependent on regulatory approvals and market adoption.
• Technological Advancements: Continuous improvement and innovation in visual prosthetic technology can drive growth. This includes enhancing the resolution, functionality, and user experience of the Orion system. Research and development efforts can focus on improving the biocompatibility of the implant, increasing the number of electrodes for finer visual perception, and developing more sophisticated image processing algorithms. Timeline: Ongoing, driven by research and development investments.
• Expansion of Indications: Expanding the indications for the Orion system to include other causes of blindness and visual impairment can broaden the addressable market. This requires conducting clinical trials to demonstrate the safety and efficacy of the system for new patient populations. Potential indications include macular degeneration, retinitis pigmentosa, and other inherited retinal diseases. Timeline: Dependent on clinical trial outcomes and regulatory approvals.
• Strategic Partnerships: Forming strategic partnerships with research institutions, hospitals, and other medical device companies can accelerate growth. These partnerships can provide access to new technologies, clinical expertise, and distribution channels. Collaboration with universities and research centers can facilitate the development of next-generation visual prosthetics. Timeline: Ongoing, dependent on identifying and securing suitable partnerships.
• Geographic Expansion: Expanding into new geographic markets can drive revenue growth. This requires obtaining regulatory approvals in each target market and establishing a local sales and marketing presence. Potential markets include Europe, Asia, and Latin America. Each market has its own regulatory requirements and competitive landscape. Timeline: Dependent on regulatory approvals and market entry strategies.

What Threats Does EYES Face?

• Competition from alternative therapies.
• Regulatory hurdles and delays.
• Product liability risks.
• Economic downturn affecting healthcare spending.

What Are EYES's Competitive Advantages?

• Proprietary technology in visual prosthetics.
• Intellectual property protection through patents.
• First-mover advantage in the cortical stimulation field.
• Established relationships with key opinion leaders.

What Does EYES Do?

Second Sight Medical Products, Inc., founded in 1998 and headquartered in Sylmar, California, specializes in the development, manufacturing, and marketing of implantable visual prosthetics designed to restore a degree of artificial vision to blind individuals. The company's core technology centers around the Orion Visual Cortical Prosthesis System, an implanted cortical stimulation device. This system is intended to provide useful artificial vision to individuals who have lost their sight due to various conditions, including glaucoma, diabetic retinopathy, optic nerve injury or disease, and eye injury. The Orion system bypasses the damaged retina and optic nerve, directly stimulating the visual cortex of the brain. This approach aims to provide a form of artificial vision, enabling patients to perceive patterns of light and potentially navigate their environment more effectively. Second Sight's focus is on addressing the unmet needs of the sight-impaired population through innovative technological solutions. As of August 30, 2022, Second Sight Medical Products, Inc. was acquired by Nano Precision Medical, Inc., in a reverse merger transaction.

What Products and Services Does EYES Offer?

• Develops implantable visual prosthetics.
• Manufactures visual prosthetics devices.
• Markets visual prosthetics to treat blindness.
• Offers the Orion Visual Cortical Prosthesis System.
• Targets individuals blind due to glaucoma.
• Aims to help those with diabetic retinopathy.
• Provides solutions for optic nerve injury or disease.
• Addresses vision loss from eye injury.

How Does EYES Make Money?

• Develops and manufactures the Orion Visual Cortical Prosthesis System.
• Sells the Orion system to hospitals and clinics.
• Provides training and support to surgeons and patients.
• Generates revenue through the sale of implantable devices.

What Industry Does EYES Operate In?

Second Sight Medical Products operates within the medical devices industry, specifically focusing on visual prosthetics. This sector is characterized by technological innovation, high research and development costs, and stringent regulatory requirements. The market for visual prosthetics is relatively small but has the potential for significant growth as technology advances and the aging population increases. Competition includes companies developing alternative therapies for blindness and visual impairment. The industry is also influenced by advancements in neuroscience and neurotechnology.

Who Are EYES's Key Customers?

• Hospitals and clinics specializing in ophthalmology.
• Surgeons who perform retinal and cortical implants.
• Patients who are blind due to various causes.
• Research institutions conducting clinical trials.

Second Sight Medical Products, Inc. (EYES) Valuation Context

Valued at $3.61M, EYES is classified as a micro-cap stock. Relative to its peer group, EYES's quantitative score of 43/100 is roughly in line with the peer average of 50/100.

Key Financial Metrics

Return on assets is -64.0%, showing how much profit it generates from its asset base. A current ratio of 3.18 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -151.6%, the inverse of the P/E and a quick read on earnings relative to price.

EYES Financials

EYES Latest News

No recent news available for EYES.

EYES Analyst Consensus

EYES MoonshotScore

EYES Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources